P22-921
Проводит AbbVie Inc.
Страница компанииProspective Real World Study Of Upadacitinib in Ulcerative Colitis (PROFUNDUS)
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT05494606/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Исследование идёт.
- Возраст участников: 18–75 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 785 чел. во всех странах исследования.
- Центров в реестре: 1 в одном городе. Список — ниже на странице.
- Плановое окончание — 03.2028.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 6 · невключение: 3
Критерии включения
- Participants with a diagnosis of moderate to severe Ulcerative colitis (UC).
- Participants initiating upadacitinib at the clinician's discretion as part of their routine clinical care; the decision to administer upadacitinib must be made prior to and independent of recruitment into the study.
- Participants prescribed upadacitinib in accordance with the approved local label.
- Participants able to understand and communicate with the investigator and comply with the requirements of the study.
- Participants willing to continue with study documentation after cessation of upadacitinib.
- Participants willing and able to participate in the collection of patient-reported data via cloud based mobile application using the provided smart device (iPhone).
Критерии невключения
- Participants with any contraindication to upadacitinib.
- Participants previously exposed to upadacitinib in a clinical trial.
- Participants currently participating in interventional research (not including noninterventional study, postmarketing observational study (PMOS), or registry participation).
Источник: ClinicalTrials.gov, NCT05494606 · запись обновлена в реестре 28 февраля 2025.
Дизайн и результаты
Что измеряют — первичные конечные точки (2)
- Median Time to Achieve the First Clinical Response (CR) per Partial Adapted Mayo Score — Up to approximately week 156
- Percentage of Participants Achieving Clinical Response (CR) per Partial Adapted Mayo Score Among those who Achieved CR at Completion of Upadacitinib Induction (either at Week 8 or at Week 16) — Week 52
Цель исследования
Ulcerative colitis (UC) is an idiopathic, chronic, inflammatory disease affecting the colon. Participants with UC have mucosal inflammation starting in the rectum that can extend continuously to proximal segments of the colon. This study will assess how safe and effective upadacitinib is in treating adult participants with moderate to severe ulcerative colitis (UC). Adverse events and change in disease activity will be assessed.
Upadacitinib is a drug approved for the treatment of Ulcerative colitis (UC). All study participants will receive upadacitinib as prescribed by their study doctor in accordance with approved local label. Approximately 1000 adult participants will be enrolled worldwide.
Participants will receive upadacitinib as prescribed by their physician according to their routine clinical practice and local label. Participants will be followed for up to 3 years.
There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.
Где проходит
1 центр в 1 городеОткуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT05494606 Официальный реестр (США) · загружено 9 ноября 2026Номер протокола, название, цель, статус, сроки, число участников, спонсор, центры
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.